Company news

Ironwood Pharmaceuticals, Inc. news in 2023

Ironwood Pharmaceuticals, Inc.'s news releases, calls and decks from 2023, newest first.

View company

Ironwood Announces the Completion of Squeeze-Out Merger With VectivBio

December 11, 2023

Ironwood Pharmaceuticals to Participate in the Piper Sandler 35th Annual Healthcare Conference

November 20, 2023

Ironwood Pharmaceuticals Reports Third Quarter 2023 Results

November 8, 2023

Ironwood Pharmaceuticals to Host Third Quarter 2023 Investor Update Call

October 25, 2023

Ironwood Releases New IBS-C and CIC Data at the American College of Gastroenterology 2023 Annual Scientific Meeting

October 22, 2023

Ironwood Pharmaceuticals Presents Positive Final Data from STARS Nutrition, a Phase II Study of Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF) and Colon in Continuity (CIC) at United European Gastroenterology Week

October 15, 2023

Ironwood to Present New Data at NASPGHAN Annual Meeting Reinforcing Impact of Linaclotide on Functional Constipation in Children and Adolescents Ages 6-17 Years-Old

October 4, 2023

Ironwood Pharmaceuticals Reports Second Quarter 2023 Results; Raises Full Year 2023 LINZESS® U.S. Net Sales and Ironwood Revenue Guidance

August 7, 2023

Ironwood Pharmaceuticals to Host Second Quarter 2023 Investor Update Call

July 24, 2023

Ironwood and VectivBio Announce the Completion of the Tender Offer for VectivBio Shares

June 28, 2023

Ironwood and VectivBio Announce Expiration of Hart-Scott-Rodino Waiting Period for Proposed Acquisition of VectivBio

June 15, 2023

Ironwood Pharmaceuticals Announces FDA Approval of New Indication for LINZESS® (linaclotide) for the Treatment of Functional Constipation in Pediatric Patients Ages 6-17 Years-Old

June 11, 2023

Ironwood Enters into Definitive Agreement to Acquire VectivBio, a Clinical-Stage Biotech Company Pioneering Novel Treatments for Severe Rare Gastrointestinal Diseases

May 21, 2023

Ironwood Pharmaceuticals to Participate in The JMP Securities Life Sciences Conference

May 8, 2023

Ironwood Presents New Data on Potential of Linaclotide for Functional Constipation in Children and Adolescents Ages 6-17 Years-Old at Digestive Disease Week® 2023

May 7, 2023

Ironwood Pharmaceuticals Reports First Quarter 2023 Results; Maintains Full Year 2023 Financial Guidance

May 3, 2023

Ironwood to Present New Data at Digestive Disease Week® 2023 Demonstrating Potential of Linaclotide for Functional Constipation in Children and Adolescents Ages 6-17 Years-Old

April 23, 2023

Ironwood Pharmaceuticals to Host First Quarter 2023 Investor Update Call

April 19, 2023

Ironwood Pharmaceuticals to Participate in Upcoming Investor Conferences

February 26, 2023

Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Results

February 15, 2023

Ironwood Pharmaceuticals Announces FDA Filing Acceptance and Priority Review of Supplemental New Drug Application for LINZESS® (linaclotide) for Functional Constipation in Children and Adolescents Ages 6-17 Years-Old

February 12, 2023

Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2022 Investor Update Call

February 1, 2023

Ironwood Pharmaceuticals Provides Update on FY 2022 Financial Guidance and Announces FY 2023 Financial Guidance

January 8, 2023

Ironwood Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference

January 3, 2023

Calls in 2023

Decks in 2023